Last updated: 26 June 2019 at 12:24am EST

Eric S Hoffman Net Worth




The estimated Net Worth of Eric S Hoffman is at least $0 dollars as of 7 November 2016. Eric Hoffman owns over 7,000 units of Genocea Biosciences Inc stock worth over $0 and over the last 10 years Eric sold GNCA stock worth over $0.

Eric Hoffman GNCA stock SEC Form 4 insiders trading

Eric has made over 1 trades of the Genocea Biosciences Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Eric bought 7,000 units of GNCA stock worth $24,430 on 7 November 2016.

The largest trade Eric's ever made was buying 7,000 units of Genocea Biosciences Inc stock on 7 November 2016 worth over $24,430. On average, Eric trades about 1,000 units every 0 days since 2014. As of 7 November 2016 Eric still owns at least 11,790 units of Genocea Biosciences Inc stock.

You can see the complete history of Eric Hoffman stock trades at the bottom of the page.



What's Eric Hoffman's mailing address?

Eric's mailing address filed with the SEC is 100 Acorn Park Dr 5th floor, Cambridge, MA 02140, USA.

Insiders trading at Genocea Biosciences Inc

Over the last 11 years, insiders at Genocea Biosciences Inc have traded over $9,875,933 worth of Genocea Biosciences Inc stock and bought 177,421,644 units worth $259,728,894 . The most active insiders traders include Forest Baskett, Scott D Sandell et Anthony A. Jr. Florence. On average, Genocea Biosciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $0. The most recent stock trade was executed by Diantha Duvall on 2 June 2022, trading 1,355 units of GNCA stock currently worth $81.



What does Genocea Biosciences Inc do?

Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.



Complete history of Eric Hoffman stock trades at Genocea Biosciences Inc

Initié
Trans.
Transaction
Prix ​​total
Eric S Hoffman
Chief Business Officer
Acheter $24,430
7 Nov 2016


Genocea Biosciences Inc executives and stock owners

Genocea Biosciences Inc executives and other stock owners filed with the SEC include: